Simvastatin enhances bone morphogenetic protein receptor type II expression
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Hu, H., Sung, A., Zhao, G. H., Shi, L. F., Qiu, D. M., Nishmura, T., Kao, P. N.
2006; 339 (1): 59-64
Abstract
Statins confer therapeutic benefits in systemic and pulmonary vascular diseases. Bone morphogenetic protein (BMP) receptors serve essential signaling functions in cardiovascular development and skeletal morphogenesis. Mutations in BMP receptor type II (BMPR2) are associated with human familial and idiopathic pulmonary arterial hypertension, and pathologic neointimal proliferation of vascular endothelial and smooth muscle cells within small pulmonary arteries. In severe experimental pulmonary hypertension, simvastatin reversed disease and conferred a 100% survival advantage. Here, modulation of BMPR2 gene expression by simvastatin is characterized in human embryonic kidney (HEK) 293T, pulmonary artery smooth muscle, and lung microvascular endothelial cells (HLMVECs). A 1.4kb BMPR2 promoter containing Egr-1 binding sites confers reporter gene activation in 293T cells which is partially inhibited by simvastatin. Simvastatin enhances steady-state BMPR2 mRNA and protein expression in HLMVEC, through posttranscriptional mRNA stabilization. Simvastatin induction of BMPR2 expression may improve BMP-BMPR2 signaling thereby enhancing endothelial differentiation and function.
View details for DOI 10.1016/j.bbrc.2005.10.187
View details for Web of Science ID 000233944500010
View details for PubMedID 16297860
